Organization
Geneplus-Beijing, Beijing, China
3 abstracts
Abstract
Liquid biopsy-based prediction of clinical benefit from immune checkpoint inhibitors in advanced biliary tract cancer.Org: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Geneplus-Beijing, Beijing, China, Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Severe and Rare Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China,
Abstract
Prospective dynamic sampling and molecular residual disease monitoring to predict clinical outcomes for patients with unresectable, locally advanced non-small cell lung cancer undergoing radical radiotherapy.Org: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Southern Medical University, Geneplus-Beijing, Beijing, China, Geneplus-Beijing Institute,
Abstract
Use of circulating tumor DNA analysis to predict recurrence and need for adjuvant chemotherapy in stage I-IV colorectal cancer.Org: Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China, Department of Colorectal & Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Geneplus-Beijing, Beijing, Beijing, China, Geneplus-Beijing, Beijing, China, Department of General Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China,